Table 2: Results.

Patients ( )Group A ( )Group B ( ) value

Study periodJan 99–Dec 06Jan 98–Dec 06
Mean followup (years; range) (3.8–11.8) (4–12.6)
Mean SCr (mg/dL) at
 1 year NS
 3 years NS
 5 years NS
 7 years NS
 10 years NS
Predominant biopsy findings—percentage
Acute rejection episodes—percentage
Bcell mediated8.3 ( )15.2 ( )NS
Tcell mediated8.3 ( )17.7 ( )0.03
Suspicious T/B9.8/0 ( /0)20.2/5 ( /4)0.024/0.022
Acute CNI toxicity12.1 ( )19 ( )NS
Recurrence1.5 ( )2.5 ( )NS
Chronic rejections
 Bcell mediated3 ( )6.3 ( )NS
 Tcell mediated3.8 ( )11.4 ( )0.029
 IFTA8.3 ( )19 ( )0.018
 Chronic CNI toxicity9.1 ( )16.5 ( )NS
 Recurrence2.3 ( ) (ATIN)3.8 ( (ATIN), (MPGN))NS
 De novo nephropathy1 (MN)0NS
 Chronic liver failure dueto reactivation22 ( )31 ( )

Abbreviations: CNI: calcineurin inhibitor; CGN: chronic glomerulonephritis; CsA: cyclosporin A; ELISA: enzyme linked immunoassay; ESRD: end-stage renal disease; G-CSF: granulocyte colony stimulating factor; HCV: hepatitis C virus; IFTA: unexplained interstitial fibrosis and tubular atrophy; LCM: lymphocyte cross-matching; PBSC: peripheral blood stem cells; POD: postoperative day; RTx: renal transplantation; SCr: serum creatinine; TIP: tolerance induction protocol.